Research on chemotherapy and its side effects. Covers nerve-injury prevention, gold-nanorod therapy, less-intensive regimens, and combination treatments.
A study found that breast cancer patients with higher body mass index (BMI) are more likely to experience heart damage, or cardiotoxicity, during chemotherapy. The study suggests that addressing obesity and considering the potential risk of cardiotoxicity requires a comprehensive approach.
Brigham researchers use induced pluripotent stem cells to restore hormone production and fertility in mice with premature ovarian failure. The study shows promise for treating incurable conditions and may lead to new therapies for patients with ovarian failure.
Researchers from Korea University Medicine have discovered a potential therapeutic target for overcoming cisplatin resistance and neuropathic pain in cervical cancer. By inhibiting TRPV1, they found that resistant tumors became vulnerable to cisplatin, improving the outlook for patients.
Scientists identified a process by which enzymes help prevent heart damage in chemotherapy patients. Enzymes normally found in mitochondria move to the nucleus, keeping cells alive. This discovery suggests new methods for testing individual patient responses and potentially preventing heart damage from chemotherapy.
Researchers report a case of a 15-year-old boy with recurrent intrathoracic synovial sarcoma who achieved partial response with BRAF inhibitor Vemurafenib treatment. The study highlights the importance of routine next-generation sequencing to drive treatment choice and investigate BRAF mutations in SS tumors.
The updated guidelines urge the clinical use of validated geriatric assessments (GA) to guide treatments in patients aged 65 and older. This approach often results in de-escalation or reduction of therapies, reducing side effects and improving quality of life without compromising survival odds.
A synoptic report improved the completeness of pretreatment CT reports in patients with advanced ovarian cancer. Involvement of surgically established unresectable or challenging-to-resect disease sites was mentioned in all disease-specific synoptic reports, compared to 37% of simple structured reports.
Researchers at the University of Alberta have discovered a correlation between chemotherapy-induced changes to gut bacteria and unhealthy weight gain in breast cancer patients. The study found that these patients gained abdominal fat and experienced inflammation, with significant changes to their gut microbiome.
Researchers at Moffitt Cancer Center found that higher c-reactive protein levels were associated with greater depression and less physical activity among patients with gynecologic cancers. However, most inflammatory markers were not linked to treatment-related symptoms.
Researchers have identified a biomarker called CXCL-9 that can be used to diagnose acute tubulointerstitial nephritis (AIN), a condition causing inflammation of the kidneys. The biomarker can be detected via a simple urine test, potentially reducing the need for kidney biopsies.
A Mayo Clinic study reveals that minimally invasive surgical procedure staging laparoscopy can identify cancer spread early and determine the stage of pancreatic cancer. The research found a higher risk of cancer spread in patients with certain factors, such as age and tumor markers.
Research suggests that glioblastoma cells possess large-scale coordination, allowing them to respond unison to therapies. Disrupting this organization may result in more powerful treatments for brain tumors.
Researchers explore pyroptosis as a potential therapeutic approach for lung cancer treatment. The review highlights the dual role of pyroptosis in tumor progression and negative impact on normal cells. It suggests balancing the contradictory effects of pyroptosis to optimize clinical applications.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
The study found that drug-resistant Leishmania parasites have distinct protein production profiles compared to sensitive parasites, suggesting a global reprogramming of protein synthesis. This pre-emptive adaptation enables the parasite to quickly respond to the presence of the drug and survive when it is absent.
Recent studies in the New Journal of Pharmaceutical Analysis feature novel diagnostic tools, RNA sequencing-based workflows, and mechanical property evaluations to enhance cancer and cardiovascular disease treatment outcomes. These innovations aim to improve the therapeutic effect of drugs and promote personalized medicine.
Researchers found that combining radiation with a genetically engineered oncolytic vaccinia virus improved treatment outcomes for glioblastoma brain tumors in mice. The combination showed a 15% cure rate and 62% rejection of new cancer cells, outperforming radiation alone.
A study by Martin-Luther-University Halle-Wittenberg found a link between high levels of IGF2BP2 and faster-growing bowel cancer tumours with chemotherapy resistance. The protein's role in cell growth and metabolism may lead to the development of new diagnostic procedures and therapeutic strategies.
Researchers from Medical College of Wisconsin found that older breast cancer survivors, particularly those exposed to chemotherapy, showed greater epigenetic aging than their same-aged peers without cancer. This acceleration in biological aging may be associated with worse functional outcomes and quality of life for these patients.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
Researchers created a new type of wound dressing material using advanced polymers, enabling customized dressings with fine-tuned surface adhesion. The material has potential applications in burn treatment and drug delivery for cancer patients, providing constant medication release outside the clinic setting.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.
A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.
The nucleus is metabolically active and uses antioxidant enzymes to repair DNA damage. Cells relocate mitochondrial machinery to the nucleus in response to DNA damage, highlighting a paradigm shift in cellular biology.
A large study tracked CIPN in over 1,100 breast cancer patients treated with taxanes, showing persistent sensory and motor symptoms with more severe symptoms with paclitaxel than docetaxel. The study defines a risk prediction model to help doctors individualize patient care.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
UMC Utrecht researchers are conducting two new projects to treat cancer using image-guided interventions. One project uses MRI-guided radiotherapy for locally advanced pancreatic cancer, while the other employs ultrasound techniques for head and neck cancers.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
Researchers have developed new methods to analyze dry-coated drug particles using 3D Raman mapping, which can effectively slow down dissolution rates. Another study introduces a novel technique for detecting complex traditional Chinese medicines, preventing adulteration and counterfeiting.
A new Northwestern Medicine study found young adult cancer survivors (18-39 years old) are 2.6 times more likely to develop heart failure when treated with anthracyclines. The incidence is highest among leukemia and other specific cancer types.
Researchers at USC Norris Comprehensive Cancer Center have identified a biomarker, CX3CR1, that can predict which patients with non-small cell lung cancer will respond well to chemoimmunotherapy. Elevated levels of the biomarker in T-cells after six to nine weeks of treatment indicate long-term benefits from the combination therapy.
Researchers from Amsterdam UMC and Copenhagen University have found that a chemofree drug-combination therapy is more effective than traditional chemotherapy in treating CLL, resulting in reduced side effects and improved patient outcomes. The study, the largest ever conducted on CLL, involved 920 fit patients and showed that treatment...
A recent clinical trial showed that cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer, improving their quality of life. The treatment also reduced symptoms such as pain and cough, and delayed clinically meaningful deterioration.
A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...
A phase 2 clinical trial testing a treatment combining standard chemotherapy with azacitidine showed nearly 90% of patients with aggressive T-cell lymphoma achieved complete remission. The treatment, which targets gene-silencing marks on DNA, has an estimated two-year progression-free survival rate of 69.2%.
Scientists successfully opened the blood-brain barrier using a novel ultrasound device, delivering chemotherapy to treat glioblastoma patients. The treatment increased drug concentrations by 4-6 times and was safe and well-tolerated.
Researchers have identified 11 somatic mutations in the RAS/MAPK pathway that contribute to treatment-resistant adult epilepsy, suggesting the potential for repurposed anti-cancer agents as new treatments. This study provides insight into the genetic mechanisms underlying this form of epilepsy and opens up new avenues for targeted ther...
A new study found that cannabis use by cancer patients leads to reduced pain levels, improved sleep quality, and enhanced cognitive function. After two weeks of sustained use, patients reported better thinking clarity and objective measures of cognition also showed improvements.
Researchers found that spinal cord stimulation reduced pain response in rats with human lung cancer tissue without compromising paclitaxel effectiveness. The study also showed SCS improved antitumor efficacy of paclitaxel, providing evidence for its potential as a companion treatment.
An international study of 1,044 patients with head and neck squamous cell carcinoma found that combining radiotherapy with chemotherapy significantly improves survival rates compared to radiotherapy alone. The benefit was particularly notable in patients between 65-79 years old with good general health.
Research suggests that patients with advanced melanoma who receive immunotherapy medications may benefit from maintaining normal vitamin D levels. The study found a favorable response rate in 56% of patients with normal baseline vitamin D levels, compared to 36% with low levels.
Researchers developed a gene signature called CisSig to predict cancer patients' response to cisplatin. The approach aims to overcome the obstacle of interpreting gene signatures in the human body and has been validated in muscle-invasive bladder cancer patients.
Researchers discuss rapamycin's potential to delay cancer onset by slowing cell proliferation and tumor progression. The mTOR pathway is involved in both cancer and aging, making rapamycin a promising chemopreventive agent.
A new meta-analysis finds that Black patients are 71% more likely to experience heart damage following chemotherapy treatment. The study highlights the need for further research into underlying factors contributing to these disparities to reduce cardiovascular risk associated with chemotherapy.
Researchers developed a chelator-free-radiolabeled polymersome capable of long-term multiday PET imaging in vivo. The nanovesicle meets key requirements for targeted cancer therapy, including precision targeting, stable radiotracer binding, and biocompatibility.
The new American Heart Association scientific statement emphasizes the importance of including non-biological factors and social determinants in CVD risk assessment for women. These factors include economic stability, neighborhood safety, education level, and access to quality healthcare, which disproportionately affect women from dive...
Researchers at Mayo Clinic Arizona have developed a new intravesical chemotherapy delivery system called TAR-200, which is safe and shows initial evidence of effectiveness in treating muscle-invasive bladder cancer (MIBC) in frail patients. The treatment has been shown to limit cancer growth while minimizing toxic effects.
A team of scientists from City University of Hong Kong and HKUST discovered novel, tridimensional compounds with high anticancer activity and low toxicity. These compounds can overcome drug resistance in cancer cells by inducing a different cell death pathway.
Researchers developed a complex that accumulates in tumour tissue and is activated by ultrasound waves, triggering the release of a toxic compound and eradicating tumours. This method could make cancer treatment less invasive and more effective for large and deep-seated tumours.
Cancer-associated fibroblasts (CAFs) are a type of cell that plays a crucial role in the tumor microenvironment. The authors suggest that understanding CAFs is essential for developing effective cancer therapies. Research targeting CAFs has shown promise, but challenges remain due to their complex nature.
A UNIGE team created customizable treatments by testing drugs on artificial tumors derived from patients' cancer tissue. The approach opens the way for optimized and tailored therapies against various cancers and diseases.
Researchers have shown lorlatinib to be safe and effective in treating high-risk neuroblastoma with ALK gene mutations. The targeted therapy has led to a major amendment in a phase 3 clinical trial, offering new hope for patients with this often lethal cancer.
Researchers from Tokyo University of Science reveal the crystal structure of centromere-associated protein E (CENP-E), a promising target for inhibitor therapy. The discovery is expected to facilitate the development of anticancer drugs with fewer adverse effects on patients.
Researchers at Rice University have created a new technology called PULSED that can deliver time-released drugs and vaccines for extended periods. The technology uses high-resolution 3D printing and soft lithography to produce microcylinders made of biodegradable polymers, which can be loaded with drugs and release them over time.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
This study of 690 patients with early-stage breast cancer found racial disparities in pathological complete response to neoadjuvant chemotherapy, affecting survival outcomes. Racial disparities varied across different breast cancer subtypes and highlight the importance of understanding tumor biology.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.
A literature review published by the Society of Nuclear Medicine and Molecular Imaging reveals how nuclear medicine brain imaging can help evaluate biological changes causing chemotherapy-related cognitive impairment. The findings confirmed the impact of chemotherapy drugs on cognitive function and highlighted the utility of various SP...
ENZAMET, a new drug combination, has shown significant improvement in survival rates for men with advanced prostate cancer. After five years, the treatment led to a 67% survival rate, compared to 57% for standard therapy.